Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Hypercholesterolaemia; Intracranial-Arteriosclerosis; Peripheral arterial disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEAR Outcomes; CVOT
  • Sponsors Esperion Therapeutics

Most Recent Events

  • 13 May 2026 According to an Esperion Therapeutics media release, data from this study will be presented at the European Atherosclerosis Society (EAS) Congress 2026 taking place on May 24-27, 2026, in Athens, Greece.
  • 30 Mar 2026 According to an Esperion Therapeutics media release, data were presented as moderated poster presentations at the American College of Cardiology's Annual Scientific Session (ACC.26) 2026.
  • 30 Mar 2026 Results published in the Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top